Drug Chatter -- Tracking biopharma stock chatter

💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…

Profile for Alexion Pharmaceuticals, Inc. (ALXN)

« Back to company index

ALXN Chatter Timeline

Stock Ticker for ALXN

Most Active Tweeters for ALXN

UserTweets
@stockmktgenius 10
@kwhenfinance 7
@FlashAlert_me 4
@soumyajyoti_b 4
@Tickeron 4

Recent Tweets for ALXN

Tickeron @Tickeron
$ALXN in Downtrend: its price may drop because broke its higher Bollinger Band on January 19, 2021. View odds for t… https://t.co/SV5wdYqVgT
January 23rd 2021, 4:01am
stockmktgenius @stockmktgenius
$ALXN Alexion Pharmaceuticals, Top stock up 111% from low. Close: 159.73 VolvsAvg: 0.79 Liq: $413M https://t.co/wMy1spFJMS
January 23rd 2021, 12:01am
stockmktgenius @stockmktgenius
$ALXN Alexion Pharmaceuticals, Leading stock #BreakOutWatch Recent close 159.73 Liquidity: $413M https://t.co/wMy1spFJMS
January 22nd 2021, 11:01pm
Testson15 @Testson15
$ALXN: ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - CHNG, OXFD, SMTX, OBLN, ALXN, BYFC,
January 22nd 2021, 4:01pm
portefeuillefun @portefeuillefun
Sold 1.9k $ALXN at $159.25, now 0.1k #vssporte shares.
January 22nd 2021, 3:01pm
kwhenfinance @kwhenfinance
Alexion Pharmaceuticals Inc. Shares Near 52-Week High - Market Mover https://t.co/f23GDkEgyB $ALXN #stockmarket #kwhenfinance
January 22nd 2021, 1:01pm
tradersreport @tradersreport
RT @Tickeron: $ALXN in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators: https://t.co/JsjDdgvYHJ #Al…
January 22nd 2021, 6:01am
Tickeron @Tickeron
$ALXN in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators:… https://t.co/JSwu9mOgVV
January 22nd 2021, 6:01am
stockmktgenius @stockmktgenius
$ALXN Alexion Pharmaceuticals, Leading stock #BreakOutWatch Recent close 157.86 Liquidity: $555M https://t.co/wMy1spFJMS
January 21st 2021, 11:01pm
optioncharts @optioncharts
$ALXN open interest for maturity 01/22/2021. High put=155.00 High call=157.50 PutCallRatio=0.57 #maxpain #options… https://t.co/CkJv15nebz
January 21st 2021, 5:01pm
kwhenfinance @kwhenfinance
Alexion Pharmaceuticals Inc. Shares Approach 52-Week High - Market Mover https://t.co/GbAPjtxdQl $ALXN #stockmarket #kwhenfinance
January 21st 2021, 1:01pm
ChartMill @ChartMill
$ALXN is currently trading near its 52 week high, which is a good sign. https://t.co/vboQ3Oiga1 https://t.co/1YSjrs0miq
January 21st 2021, 8:01am
stockmktgenius @stockmktgenius
$ALXN Alexion Pharmaceuticals, Leading stock #BreakOutWatch Recent close 157.74 Liquidity: $561M https://t.co/wMy1spFJMS
January 20th 2021, 11:01pm
oye10984348 @oye10984348
@NickLandis1 Been a while since I saw their data. Their drug did better vs $alxn in treatment-resistant Pnh folks… https://t.co/KYDRN3JBl7
January 20th 2021, 11:01pm
communiststocks @communiststocks
Alexion Pharmaceuticals - $ALXN ? QUOTE $ALXN was UP ? on Tue Jan 19 Closed at 158.71 USD for a 1.28% gain from pr… https://t.co/zfmyNWaOxf
January 20th 2021, 6:01am
stockmktgenius @stockmktgenius
$ALXN Alexion Pharmaceuticals, Leading stock #BreakOutWatch Recent close 158.71 Liquidity: $577M https://t.co/wMy1spFJMS
January 19th 2021, 11:01pm
TradeWithAlerts @TradeWithAlerts
Large Print $ALXN Size: 144332 Price: 158.71 Time: 1726 Amount: $22,906,931.72
January 19th 2021, 10:01pm
Tickeron @Tickeron
$ALXN in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators:… https://t.co/3848OF4ibc
January 19th 2021, 6:01am
stockmktgenius @stockmktgenius
$ALXN Alexion Pharmaceuticals, Leading stock #BreakOutWatch Recent close 156.70 Liquidity: $331M https://t.co/wMy1spFJMS
January 18th 2021, 11:01pm
DataTrials @DataTrials
$ALXN Phase 3 Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of… https://t.co/YIVZ7MZuL5
January 17th 2021, 5:01pm
DataTrials @DataTrials
$ALXN Phase 1 Study of Radiolabeled ALXN2050 in Healthy Adult Males…NCT04609670. Estimated Primary Completion Date - 02/2021
January 17th 2021, 5:01pm
kwhenfinance @kwhenfinance
Alexion Pharmaceuticals Inc. Shares Close in on 52-Week High - Market Mover https://t.co/xaXLf7uRYR $ALXN #stockmarket #kwhenfinance
January 16th 2021, 1:01pm
PicksSwag @PicksSwag
RT @stockmktgenius: $ALXN Alexion Pharmaceuticals, Leading stock #BreakOutWatch Recent close 156.70 Liquidity: $286M https://t.co/wMy1spFJ…
January 15th 2021, 11:01pm
stockmktgenius @stockmktgenius
$ALXN Alexion Pharmaceuticals, Leading stock #BreakOutWatch Recent close 156.70 Liquidity: $286M https://t.co/wMy1spFJMS
January 15th 2021, 11:01pm
kwhenfinance @kwhenfinance
Alexion Pharmaceuticals Inc. Shares Near 52-Week High - Market Mover https://t.co/QX49A9HR5u $ALXN #stockmarket #kwhenfinance
January 15th 2021, 12:01pm
stockmktgenius @stockmktgenius
$ALXN Alexion Pharmaceuticals, Leading stock #BreakOutWatch Recent close 156.65 Liquidity: $496M https://t.co/wMy1spFJMS
January 14th 2021, 11:01pm
StockTexts @StockTexts
$ALXN Alexion Pharmaceuticals, Inc. SEC Filing: Form 425 https://t.co/hfK06OeNhr
January 14th 2021, 10:01pm
StckPro @StckPro
$ALXN NEW ARTICLE : INVESTIGATION ALERT: Halper Sadeh LLP Investigates ALXN, CHNG, RP, RNET, MDCA, NK; Shareholders… https://t.co/vzttTEUF79
January 14th 2021, 10:01pm
Testson15 @Testson15
$ALXN: INVESTIGATION ALERT: Halper Sadeh LLP Investigates ALXN, CHNG, RP, RNET, MDCA, NK; Shareholders Are Encouraged to Contact the
January 14th 2021, 9:01pm
MarcJacksonLA @MarcJacksonLA
$ALXN Ultomiris falls short in COVID-19 trial after months of testing in severe patients https://t.co/4eyH8MHDou
January 14th 2021, 8:01pm
RJ248842 @RJ248842
From $APLS JPM presentation: matching adjusted indirect comparison of pegcetacoplan (APL-2) and $ALXN Ultomiris. No… https://t.co/meHOX48RTO
January 14th 2021, 4:01pm
veeraj3103 @veeraj3103
RT @biostockguru: R/M to close ? 3M Float $6M EV 3 clinical stage programs Orbimed & Ex $ALXN Founder & Peter Thiel / Thiel Capital CMO…
January 14th 2021, 2:01pm
biostockguru @biostockguru
R/M to close ? 3M Float $6M EV 3 clinical stage programs Orbimed & Ex $ALXN Founder & Peter Thiel / Thiel Capita… https://t.co/V6qlN35G1E
January 14th 2021, 2:01pm
OpenOutcrier @OpenOutcrier
$ALXN (+0.4% pre) Alexion Pharma (ALXN) Reports Update on Phase 3 Study of ULTOMIRIS (ravulizumab-cwvz) in Hospital… https://t.co/woGeUAE2C9
January 14th 2021, 12:01pm
kwhenfinance @kwhenfinance
Alexion Pharmaceuticals Inc. Shares Near 52-Week High - Market Mover https://t.co/MXZAgxRVEQ $ALXN #stockmarket #kwhenfinance
January 14th 2021, 12:01pm
Briefingcom @Briefingcom
$ALXN: Alexion Pharma to pause further enrollment in Phase 3 study of ULTOMIRIS in hospitalized COVID-19 patients... https://t.co/aaJz6piVPv
January 13th 2021, 11:01pm
stockmktgenius @stockmktgenius
$ALXN Alexion Pharmaceuticals, Leading stock #BreakOutWatch Recent close 156.44 Liquidity: $520M https://t.co/wMy1spFJMS
January 13th 2021, 10:01pm
fwpharma @fwpharma
Alexion's Ultomiris shows "lack of efficacy" in severe #COVID19 study $ALXN https://t.co/YQHuv2iiNu
January 13th 2021, 10:01pm
MarcJacksonLA @MarcJacksonLA
$ALXN Alexion pauses enrollment for COVID-19 study testing its rare blood-disorder drug https://t.co/0dG9Ry3CoO
January 13th 2021, 9:01pm
saltadogato @saltadogato
$ALXN Ultomiris failed in #COVID19 not shocking (and doesn't really matter to the stock b/c of the $AZN merger) https://t.co/v4w4OEScNi
January 13th 2021, 9:01pm
sbwcws @sbwcws
Alexion further pauses global Phase 3 study of Ultomiris $ALXN
January 13th 2021, 9:01pm
Allstocknews @Allstocknews
$ALXN Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with From our Stock News Alerts App
January 13th 2021, 9:01pm
theflynews @theflynews
Alexion to pause further enrollment in Phase 3 study of ULTOMIRIS $ALXN https://t.co/yfbi7za22U
January 13th 2021, 9:01pm
MarketCurrents @MarketCurrents
$ALXN - Alexion to pause further enrolment in global late-stage COVID-19 study of ULTOMIRIS https://t.co/rLJF6MQ2hF
January 13th 2021, 9:01pm
FlashAlert_me @FlashAlert_me
$ALXN [15s. delayed]: Issued Press Release on January 13, 16:20:00: Alexion Provides Update on Phase 3 Study of ULT… https://t.co/zUR39OyYr5
January 13th 2021, 9:01pm
CHItraders @CHItraders
$ALXN Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-… https://t.co/x0ddl61fWQ
January 13th 2021, 9:01pm
blackflyonpence @blackflyonpence
$ALXN NOT GOOD Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Se… https://t.co/yFye41eDfS
January 13th 2021, 9:01pm
YuZhu4 @YuZhu4
RT @BioRunUp: $ALXN - ouch Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-1…
January 13th 2021, 9:01pm
soumyajyoti_b @soumyajyoti_b
$ALXN - Alexion to pause further enrollment in Phase 3 study of ULTOMIRIS Read more at: https://t.co/ILhJtbRA4B
January 13th 2021, 9:01pm
sbwcws @sbwcws
Alexion to pause further enrollment in Phase 3 study of ULTOMIRIS $ALXN
January 13th 2021, 9:01pm

DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC 2004 - 2021. All rights reserved.